Pfizer 1Q Revenues: $13.1 billion (+2%) 1Q Earnings: $3.9 billion (+9%) Comments: Biopharma revenues were $9.2 billion in the quarter, up 3% driven by Eliquis (up 32% to $1.0 billion), Ibrance (up 21% to $1.1 billion), Prevnar 13/Prevenar 13 (+8% to $1.5 billion) and Xeljanz (+30% to $423 million). Upjohn revenues were $3.1 billion, down 1%, with growth in China, primarily from Lipitor, Norvasc and Celebrex, partially offset by 3% operational decline in developed markets excluding Japan, prim...